Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy

References

• Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; ii: 112–133
   Google Scholar
• Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful prognostic indicator in multiple myeloma. British Journal of Cancer 1992; 66: 337–341
   PubMed Web of Science ®Google Scholar
• Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasuik A. Plasma tissue inhibitor of metalloproteinase-1 and transforming growth factor β1 — possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepato-Gastroenterology 2002; 49: 1369–1372
   PubMedGoogle Scholar
• Hu KQ. A practical approach to chronic hepatitis B. International Journal of Medical Science 2005; 2: 17–23
   PubMedGoogle Scholar
• Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI. A one-year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998; 339: 61–68
   PubMed Web of Science ®Google Scholar
• Liaw YF. Management of patients with chronic hepatitis B. Journal of Gastro-Hepatology 2002; 17: 406–408
   PubMedGoogle Scholar
• Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493–496
   PubMed Web of Science ®Google Scholar
• Lin DY, Chu CM, Sheen IS, Liaw YF. Serum carboxyterminal propeptide of type 1 procollagen to amino terminal propeptide of type 111 procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases. Digestive Disease Science 1995; 40: 21–27
   PubMedGoogle Scholar
• Malaguarnera M, Restuccia S, Ferlito L, Mazzoleni G, Giugno I, Pistone G. Antiviral drugs in chronic hepatitis B: review and meta-analysis. International Journal of Clinical Pharmacology and Therapeutics 2001; 39: 4–11
   PubMedGoogle Scholar
• McMahon BJ, Alward WLM, Hall DB. Acute hepatitis B infection: relation of age to the clinical expression of the disease and subsequent development of carrier-state. Journal of Infectious Diseases 1985; 151: 599–603
   PubMed Web of Science ®Google Scholar
• Melkko J, Neimi S, Ristelli L. Radioimmunoassay of carboxy-terminal propeptide of type 1 procollagen (PICP). Clinical Chemistry 1990; 36: 1328–1332
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lim HL, Oliver D, Qian KP, Lau JYN. Alpha glutathione-S-transferase as a marker of hepatocellular damage in chronic hepatitis C. American Journal of Clinical Pathology :/198 1995; 104: 193
   PubMedGoogle Scholar
• Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186–191
   PubMed Web of Science ®Google Scholar
• Regev A, Schiff ER. Drug therapy for hepatitis B. Advances in Internal Medicine 2001; 46: 107–135
   PubMedGoogle Scholar
• Ristelli J, Niemi S, Trivedi P. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type 111 procollagen (P3NP). Clinical Chemistry 1990; 36: 421–426
   PubMedGoogle Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology 1991; 13: 372–374
   PubMed Web of Science ®Google Scholar
• Schuppan D, Besser M, Schwarting R. Radioimmunoassay for the carboxy-terminal cross-linking domain of type 1V (basement membrane) procollagen in body fluids. Journal of Clinical Investigation 1986; 78: 241–248
   PubMed Web of Science ®Google Scholar
• Shindo M, Hamada K, Nishioji K, Muramatsu A, Oda Y, Okuno T. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B. Journal of Gastroenterology 2004; 39: 260–267
   PubMedGoogle Scholar
• Suzuki Y, Kumada H, Chayama K, Arase Y, Saitoh S. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. Journal of Hepatology 1999; 30: 743–748
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD. Efficacy of lamivudine in patients with hepatitis B antigen negative hepatitis B virus DNA positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889–896
   PubMed Web of Science ®Google Scholar
• Tsutsumi M, Takase S, Urashima S, Ueshima Y, Kawahara H, Takada A. Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase or prolyl hydroxylase?. Alcoholism Clinical and Experimental Research 1996; 20: 1512–1517
   PubMed Web of Science ®Google Scholar
• Tsutsumi M, Urashima S, Matsuda Y, Takase S, Takada A. Changes in type IV collagen content in livers of patients with alcoholic liver disease. Hepatology 1993; 17: 820–827
   PubMed Web of Science ®Google Scholar
• Ueno T, Inuzuka S, Torimura T, Oohira H, Ko H, Obata K, Sata M, Yashida H, Tanikawa K. Significance of serum type IV collagen levels in various liver diseases. Scandinavian Journal of Gastroenterology 1992; 27: 513–520
   PubMed Web of Science ®Google Scholar
• Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S. Serum collagen IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scandinavian Journal of Gastroenterology 1994; 29: 474–479
   PubMed Web of Science ®Google Scholar
• Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type 111 procollagen in routine screening for methotrexate induced liver fibrosis: a 10 year follow-up. British Journal of Dermatology 2001; 143: 100–103
   Google Scholar
• Zoulim F. A preliminary benefit–risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection. Drug Safety 2002; 25: 497–510
   PubMed Web of Science ®Google Scholar